Blog
Field notes for people who track
Guides, evidence reviews, and testing literacy — written the way we build the app: cited, precise, no hype. Every empirical claim traces to a named source, and nothing here is medical advice.
Compounds
BPC-157: the gap between the rodent data and the human claims
Where the BPC-157 evidence actually stands: an extensive rodent literature, no published human efficacy trials, and a 2023 FDA compounding restriction.
Aug 11, 2026 · 8 min read
Tracking
Half-life and steady state: why week 5 feels different than week 1
How first-order elimination and the five-half-life rule explain why weekly peptides build for a month and why effects outlast the final dose by weeks.
Aug 11, 2026 · 8 min read
Testing
How to read a peptide COA: purity, mass spec, and what's missing
What a certificate of analysis proves, what HPLC purity actually measures, why net peptide content matters, and the red flags that void a COA.
Aug 11, 2026 · 8 min read
Guides
How to reconstitute peptides: the math, the technique, the mistakes
The three numbers behind every peptide draw, the arithmetic that connects them, and the reconstitution mistakes that actually change a measured dose.
Aug 11, 2026 · 7 min read
Tracking
Injection site rotation: why it matters and how to track it
Repeated same-site injections cause lipohypertrophy and erratic absorption — what the insulin literature documents, and rotation systems that actually work.
Aug 11, 2026 · 7 min read
Compounds
Lean mass loss on GLP-1s: what the trials measured
What STEP 1 and SURMOUNT-1 body-composition substudies found about lean mass, why percent-of-loss headlines mislead, and which countermeasures have evidence.
Aug 11, 2026 · 7 min read
Guides
Peptide storage: lyophilized vs reconstituted, and what actually degrades
What actually degrades a peptide — hydrolysis, oxidation, aggregation — why lyophilized vials tolerate shipping, and where the 28-day rule really comes from.
Aug 11, 2026 · 8 min read
Compounds
Retatrutide: what phase 2 actually showed, and what it didn't
What the retatrutide phase 2 trial showed — 24.2% mean weight loss at 48 weeks — and what remains unknown: long-term safety, durability, approval.
Aug 11, 2026 · 7 min read
Compounds
Semaglutide vs tirzepatide: what the head-to-head data shows
The mechanisms, the STEP 1, SURMOUNT-1, and SURPASS-2 numbers, the SURMOUNT-5 head-to-head result, and the questions the trial record leaves open.
Aug 11, 2026 · 8 min read
Tracking
The bloodwork worth running before and during a GLP-1 protocol
What the GLP-1 trial protocols measured and the semaglutide and tirzepatide labels flag — glycemic, pancreatic, liver, lipid — and why baselines matter.
Aug 11, 2026 · 7 min read
Testing
The gray-market peptide supply chain: what testing can and can't tell you
How research-chemical peptides reach buyers, what the research-use-only label means in practice, and what testing one vial can and cannot rule out.
Aug 11, 2026 · 8 min read
Guides
Units vs milligrams: the syringe math that trips everyone up
What a unit on a U-100 insulin syringe really measures, why units mean nothing without knowing concentration, and how to convert units to mL and mg.
Aug 11, 2026 · 7 min read